Samsung Biologics

Samsung Biologics Co., Ltd.
Company typePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011 (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim (president and CEO)[1]
Revenue KRW 4.55 trillion (2024) [2]
KRW 325.7 billion (2024) [2]
Owners
Number of employees
4,300 (2023)
SubsidiariesSamsung Bioepis
Websitesamsungbiologics.com

Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]

History

Facilities & Expansion

Founded in 2011,[8] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023.[9][10][11] In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. In March 2025, Samsung Biologics began operations at its dedicated antibody-drug conjugate (ADC) manufacturing facility in Songdo,[12] expanding its service capabilities into ADC production.The company now holds total capacity of 784,000 liters.

Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and Boston[14] to more closely support U.S. biopharmaceutical companies across both coasts. In 2025, Samsung Biologics also opened a regional office in Tokyo[15], Japan, to strengthen ties with Japanese pharmaceutical and biotechnology companies.

In 2025, Samsung Biologics introduced its manufacturing framework, ExellenS™, developed through the company's cumulative expertise in plant design, digitalization, and operational excellence. ExellenS™ standardizes equipment, processes, and functional specifications to enable fast tech transfers, rapid approvals, and predictable outcomes. By implementing the unified ExellenS™ model, Samsung Biologics delivers consistent results while minimizing risk.[16][17][18][19]

Notable Partnerships

As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies.[20][21] This includes early deals with Roche[22] and Bristol-Myers Squibb[23] in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta.[24] Two years later, a second $296 million deal was signed.[25]

During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax.[26][27] The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic[28] and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.[29]

In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million.[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[30]

Along with Big pharma partnerships, the company has engaged with smaller development-stage companies. In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services.[31] In February 2024, Samsung Biologics announced a partnership agreement with LigaChem (formerly LegoChem) Biosciences to provide antibody development and drug substance manufacturing services to support LigaChem's antibody-drug conjugate (ADC) pipeline.[32]

Samsung Biologics signed a 1.7 trillion won ($1.2 billion) deal with an unnamed Asian pharmaceutical company to provide contract manufacturing organization services, the largest contract secured in the company's history.[33]

Business Ventures

In 2012, it established Samsung Bioepis, a biosimilar medicine developer, as a joint venture with Biogen.[34] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[35] Samsung Biologics completed its spin-off of Samsung Bioepis.[36]

In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T.[37] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.

Platforms

Samsung Biologics has developed a range of proprietary technologies for biologics development. This includes S-CHOice, a cell line expression technology introduced in 2020.[38] In 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform,[39] and its DEVELOPICK platform, a service that selects candidate materials for new drugs. Samsung Biologics has since expanded its technology portfolio with additional platforms, including S-CHOsient[40], S-AfuCHO[41], S-Tensify[42], S-Glyn[43], S-OptiCharge[44], and S-HiCon.[45]

Sustainability

Samsung Biologics published its first annual sustainability report in June 2021. It was added to the Dow Jones Sustainability World Index later that year.[46] The company was awarded the Sustainable Market Initiative's 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.[47] In 2023, Samsung Biologics received both a leadership A− score from the Carbon Disclosure Project (CDP)[48] and an EcoVadis Gold Sustainability Rating.[49]

Samsung Biologics participates in several global sustainability and responsible-business initiatives, including the Sustainable Markets Initiative (SMI), the Pharmaceutical Supply Chain Initiative (PSCI), the Task Force on Climate-related Financial Disclosures (TCFD), RE100, the United Nations Global Compact (UNGC), Sustainalytics assessments, and EcoVadis.

Corporate governance

As of 30 June 2023.

Shareholder Stake (%) Flag
Samsung C&T 43.06%
Samsung Electronics 31.22%
National Pension Service 8.13%

See also

References

  1. ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
  2. ^ a b "Samsung Biologics reports fourth quarter and fiscal year 2024 financial results".
  3. ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  4. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
  5. ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
  6. ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
  7. ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
  8. ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  9. ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  10. ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  11. ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  12. ^ Choi, Mun-hee (2025-06-10). "Lee Jae-yong Visits State-of-the-art Samsung Biologics Plant No. 5".
  13. ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  14. ^ Hae-yeon, Kim (2025-06-19). "[Bio USA] Samsung Biologics expands strategic focus to top 40 global pharma". The Korea Herald. Retrieved 2025-12-03.
  15. ^ "Samsung Biologics Expands Presence in Japan with New Tokyo Office". biopharmaapac.com. Retrieved 2025-12-03.
  16. ^ Korea’s Samsung Biologics Introduces Optimised Manufacturing Framework ExellenS – BioSpectrum Asia
  17. ^ Samsung Biologics Introduces Optimized Manufacturing Framework ExellenS – BioSpace
  18. ^ Samsung Biologics Launches ExellenS Framework to Standardize and Accelerate Biomanufacturing Operations – Global Pharma Update
  19. ^ Samsung Biologics Launches ExellenS Framework to Standardise and Accelerate Global Biomanufacturing – PR Newswire
  20. ^ Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
  21. ^ Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". KED Global. The Korean Economic Daily.
  22. ^ Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.
  23. ^ Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.
  24. ^ Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  25. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
  26. ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma. 24 May 2021.
  27. ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald. 25 November 2021.
  28. ^ Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
  29. ^ Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
  30. ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
  31. ^ Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.
  32. ^ Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
  33. ^ "Samsung Biologics signs largest-ever $1.2 billion deal". Korea JoongAng. 2024.
  34. ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  35. ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  36. ^ Biologics, Samsung. "Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO". www.prnewswire.com. Retrieved 2025-12-03.
  37. ^ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". KED Global. The Korea Economic Daily. 30 March 2022.
  38. ^ Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  39. ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  40. ^ Team, ADC Review | Editorial (2024-01-09). "Samsung Biologics Presents 2024 Business Plans » ADC Review". ADC Review. Retrieved 2025-12-03.
  41. ^ "Samsung Biologics Introduces Advanced Development Platforms to Boost Therapeutic Efficacy". biopharmaapac.com. Retrieved 2025-12-03.
  42. ^ Hae-yeon, Kim (2024-06-04). "[Bio USA] Samsung Biologics unveils new CDO platform". The Korea Herald. Retrieved 2025-12-03.
  43. ^ Team, ADC Review | Editorial (2024-01-09). "Samsung Biologics Presents 2024 Business Plans » ADC Review". ADC Review. Retrieved 2025-12-03.
  44. ^ "Samsung Biologics Introduces Advanced Development Platforms to Boost Therapeutic Efficacy". biopharmaapac.com. Retrieved 2025-12-03.
  45. ^ "Samsung Biologics Launches High-Concentration Formulation Platform". Contract Pharma. 2024-10-14. Retrieved 2025-12-03.
  46. ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald. 14 November 2021.
  47. ^ Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.
  48. ^ Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.
  49. ^ Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Businesskorea. Business Korea.
  • Official website
  • Business data for Samsung Biologics:
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.